-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
BridgeBio Pharma, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2018 to Q4 2024.
- BridgeBio Pharma, Inc. Nonoperating Income (Expense) for the quarter ending December 31, 2024 was -$40.2M, a 667% decline year-over-year.
- BridgeBio Pharma, Inc. Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $50.8M.
- BridgeBio Pharma, Inc. annual Nonoperating Income (Expense) for 2024 was $50.8M.
- BridgeBio Pharma, Inc. annual Nonoperating Income (Expense) for 2023 was -$45.9M, a 267% decline from 2022.
- BridgeBio Pharma, Inc. annual Nonoperating Income (Expense) for 2022 was $27.6M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)